In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Biogen paid Sage $11 million in collaboration revenues in the third quarter, during which the drug made $22 million, and buying Sage would give it total control of the brand. At last week's ...

Biogen will retain its commercial rights to ... The marketed biosimilars are versions of big-selling brands, including Amgen's Enbrel (etanercept), AbbVie's Humira (adalimumab), Johnson ...

Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the ...

Biogen has refueled its R&D engine, paying Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment for Dravet ...

"Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site ...

In May 2023, after lecanemab had been granted accelerated approval for commercial use, under the brand name Leqembi, Biogen stock traded at >$315 per share, and the drug received full approval in ...

Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...

The stock's fall snapped a seven-day winning streak.

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of ...